Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Sep 1:9:963952.
doi: 10.3389/fsurg.2022.963952. eCollection 2022.

Intrahepatic sarcomatoid cholangiocarcinoma: A case report of the youngest patient on record and a review of the condition's characteristics

Affiliations
Case Reports

Intrahepatic sarcomatoid cholangiocarcinoma: A case report of the youngest patient on record and a review of the condition's characteristics

Long-Fu Xi et al. Front Surg. .

Abstract

As a rare disease, intrahepatic sarcomatoid cholangiocarcinoma (s-CCC) represents less than 1% of malignancies of the hepatobiliary system and its main clinical symptoms include abdominal pain and fever. Results of pathological examinations, despite being the "gold standard", can easily be confused with hepatocellular carcinoma (HCC). This report is about a 32-year-old male patient who was hospitalized due to occupancy of segment V of the liver for three days and had a history of chronic hepatitis B (CHB) over a 20-year span. Magnetic resonance imaging (MRI) showed a 43 mm × 52 mm-sized liver mass in the V segment, with patchy peripheral enhancement during the arterial phase and rapid wash-out during the portal and late phases. A laparoscopic hepatectomy of segment V, along with cholecystectomy, was performed. Histopathological and immunohistochemical examinations indicated a malignant neoplasm that was positive for vimentin and cytokeratin, with these features providing a positive diagnosis for intrahepatic sarcomatoid cholangiocarcinoma. After surgery, an adjuvant therapy of albumin-paclitaxel combined with gemcitabine regimen was given. No recurrence was found six months after the surgery, with follow-up still ongoing. This report aims to improve the awareness, diagnosis, and treatment of s-CCC.

Keywords: case report; hepatobiliary malignancy; immunohistochemical staining; intrahepatic sarcomatoid cholangiocarcinoma; sarcomatoid change.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Ct images of axial sections: (A) A bulky hypodense mass in segment V of the liver indicates the lesion; arterial phase (B) shown enhancement of peripheral areas and slight progressive centripetal enhancement in portal phase (C); three-dimensional reconstruction of the liver mass in segment V (43 mm × 52 mm-sized) (D).
Figure 2
Figure 2
Contrasted MRI images of the liver: (A) an abnormal signal liver mass in segment V and obvious restricted diffusion on DWI; (B) a hypointense signal and a slightly hyperintense one on T1- and T2-weighted scans respectively; (C) patchy peripheral enhancement in the arterial phase, and (D) rapid washout in the portal and late phases.
Figure 3
Figure 3
Histologic findings (hematoxylin and eosin staining, 40 × ): primary high-grade malignant tumor with patchy necrosis and abundant lymphocyte infiltration. Cancer infiltration was not observed in nerves, in vessels or at the margin of hepatectomy.

References

    1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet (London, England). (2018) 391(10127):1301–14. 10.1016/S0140-6736(18)30010-2 - DOI - PubMed
    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2021) 71:209–49. 10.3322/caac.21660 - DOI - PubMed
    1. Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol. (2018) 7(5):52. 10.21037/cco.2018.07.03 - DOI - PubMed
    1. Malhotra S, Wood J, Mansy T, Singh R, Zaitoun A, Madhusudan S. Intrahepatic sarcomatoid cholangiocarcinoma. J Oncol. (2010) 2010:701476. 10.1155/2010/701476 - DOI - PMC - PubMed
    1. Kim DK, Kim BR, Jeong JS, Baek YH. Analysis of intrahepatic sarcomatoid cholangiocarcinoma: experience from 11 cases within 17 years. World J Gastroenterol. (2019) 25:608–21. 10.3748/wjg.v25.i5.608 - DOI - PMC - PubMed

Publication types